At American Diabetes Association's 77th Scientific Sessions in San Diego
Mylan and Biocon announced the presentation of new data from the insulin glargine clinical program, including the INSTRIDE studies at the American Diabetes Association's 77th Scientific Sessions in San Diego. The studies confirmed the efficacy, safety and immunogenicity of MYL-1501D, insulin glargine, in comparision to Lantus in patients with Type 1 and Type 2 diabetes. Data demonstrating pharmacokinetic and pharmacodynamic equivalence was also presented.Insulin glargine is a long acting insulin used to treat adults with Type 2 diabetes, as well as adults and paediatric patients with Type 1 diabetes, for the control of high blood sugar.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
